Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Examining the effects of agomelatine in hyperactive patients with ADHD
IRCT20241024063486N1Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of agomelatine in attention deficit hyperactivity disorder (ADHD), sponsored by Zanjan University of Medical Sciences. Started Nov 2024; status: completed.
02
Drugs
agomelatine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on IRCT20241024063486N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241024063486N1.